ABSTRACT
Inthischapterwehavereviewed,inseparatesectionsforpotassiumchannel activators(KCAs)(sections16.1to16.4)andblockers(KCBs)(sections16.5to 16.16),clinicalexperiencesandfutureprospectsfortheiruseintherapeutics.This approachseemslogicaltousinviewofthedisparateapplicationsforthesetwodrug classes.
